ArticleThe American journal of medicine2013
Angiotensin-converting enzyme inhibitors and outcomes in heart failure and preserved ejection fraction.
Article in The American journal of medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Association is not causation: treatment effects cannot be estimated from observational data in heart failure.European heart journal · 2018Pooled it
- Effect of renin-angiotensin system inhibitors on mortality in heart failure with preserved ejection fraction: a meta-analysis of observational cohort and randomized controlled studies.Heart failure reviews · 2017Pooled it
- Renin-angiotensin blockade in heart failure with preserved ejection fraction: a systematic review and meta-analysis.ESC heart failure · 2017Pooled it
- Inappropriate pharmacological treatment in older adults affected by cardiovascular disease and other chronic comorbidities: a systematic literature review to identify potentially inappropriate prescription indicators.Clinical interventions in aging · 2017Pooled it
- Digoxin use and lower risk of 30-day all-cause readmission in older patients with heart failure and reduced ejection fraction receiving β-blockers.Clinical cardiology · 2018Trial
- Rate-control versus rhythm-control strategies and outcomes in septuagenarians with atrial fibrillation.The American journal of medicine · 2013Trial
- Patterns of use and dose optimization of renin-angiotensin system modulators among chronic heart failure patients with reduced ejection fraction in resource-limited settings: a multicenter cohort study.Therapeutic advances in chronic disease · 2025Article
- The Diabetic Cardiorenal Nexus.International journal of molecular sciences · 2022Review
- Digoxin Initiation and Outcomes in Patients with Heart Failure with Preserved Ejection Fraction.The American journal of medicine · 2020Article
- Digoxin Discontinuation and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.Journal of the American College of Cardiology · 2019Article
- Digoxin and 30-Day All-Cause Readmission in Long-Term Care Residents Hospitalized for Heart Failure.Journal of the American Medical Directors Association · 2017Article
- Characteristics, Management, and Outcomes of Acute Heart Failure in the Emergency Department: A Multicenter Registry Study with 1-year Follow-up in a Chinese Cohort in Beijing.Chinese medical journal · 2017Article
- Diagnosis and Management of Heart Failure in Older Adults.Heart failure clinics · 2017Review
- Use and Interpretation of Propensity Scores in Aging Research: A Guide for Clinical Researchers.Journal of the American Geriatrics Society · 2016Review
- Article
- Discharge Hospice Referral and Lower 30-Day All-Cause Readmission in Medicare Beneficiaries Hospitalized for Heart Failure.Circulation. Heart failure · 2015Article
- Beta-blocker Use and 30-day All-cause Readmission in Medicare Beneficiaries with Systolic Heart Failure.The American journal of medicine · 2015Article
- Orthostatic hypotension and incident heart failure in community-dwelling older adults.The journals of gerontology. Series A, Biological sciences and medical sciences · 2014Article
- Digoxin use and lower 30-day all-cause readmission for Medicare beneficiaries hospitalized for heart failure.The American journal of medicine · 2014Article
- Heart failure in very old adults.Current heart failure reports · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
backgroundThe role of angiotensin-converting enzyme (ACE) inhibitors in patients with heart failure and preserved ejection fraction remains unclear.
methodsOf the 10,570 patients aged ≥65 years with heart failure and preserved ejection fraction (≥40%) in the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients With Heart Failure (2003-2004) linked to Medicare (through December 2008), 7304 were not receiving angiotensin receptor blockers and had no contraindications to ACE inhibitors. After excluding 3115 patients with pre-admission ACE inhibitor use, the remaining 4189 were eligible for new discharge prescriptions for ACE inhibitors, and 1706 received them. Propensity scores for the receipt of ACE inhibitors, calculated for each of the 4189 patients, were used to assemble a cohort of 1337 pairs of patients, balanced on 114 baseline characteristics.
resultsMatched patients had a mean age of 81 years and mean ejection fraction of 55%, 64% were women, and 9% were African American. Initiation of ACE inhibitor therapy was associated with a lower risk of the primary composite end point of all-cause mortality or heart failure hospitalization during 2.4 years of median follow-up (hazard ratio [HR], 0.91; 95% confidence interval [CI], 0.84-0.99; P = .028), but not with individual end points of all-cause mortality (HR, 0.96; 95% CI, 0.88-1.05; P = .373) or heart failure hospitalization (HR, 0.93; 95% CI, 0.83-1.05; P = .257).
conclusionIn hospitalized older patients with heart failure and preserved ejection fraction not receiving angiotensin receptor blockers, discharge initiation of ACE inhibitor therapy was associated with a modest improvement in the composite end point of total mortality or heart failure hospitalization but had no association with individual end point components.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.